Overview
- A retrospective review of more than 1,000 MD Anderson patients found advanced lung cancer survival rose to a median 37.3 months when an mRNA COVID shot was given within 100 days of starting immunotherapy, up from 20.6 months without vaccination.
- In metastatic melanoma, patients vaccinated before initiating immunotherapy outlived unvaccinated peers, with the vaccinated group not reaching median survival after more than three years of follow-up.
- Mouse studies and immune profiling suggest mRNA vaccination activates antigen-presenting pathways and enhances T‑cell responses, helping previously unresponsive tumors respond to checkpoint blockade.
- Comparable time‑window receipt of non‑mRNA influenza or pneumococcal vaccines showed no survival benefit, pointing to a platform‑specific effect in the analysis.
- Researchers stress the evidence is observational and subject to confounding and are organizing randomized trials through the OneFlorida+ network with enrollment targeted this year, as HHS recently ended 22 federal mRNA investments.